Cargando…

DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy

DNAM-1 is a major NK cell activating receptor and, together with NKG2D and NCRs, by binding specific ligands, strongly contributes to mediating the killing of tumor or virus-infected cells. DNAM-1 specifically recognizes PVR and Nectin-2 ligands that are expressed on some virus-infected cells and on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cifaldi, Loredana, Melaiu, Ombretta, Giovannoni, Roberto, Benvenuto, Monica, Focaccetti, Chiara, Nardozi, Daniela, Barillari, Giovanni, Bei, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285446/ https://www.ncbi.nlm.nih.gov/pubmed/37359555 http://dx.doi.org/10.3389/fimmu.2023.1197053

Ejemplares similares

DNAM-1-chimeric receptor-engineered NK cells, combined with Nutlin-3a, more effectively fight neuroblastoma cells in vitro: a proof-of-concept study
por: Focaccetti, Chiara, et al.
Publicado: (2022)

Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors
por: Melaiu, Ombretta, et al.
Publicado: (2020)

CAR‐NK cell in cancer immunotherapy; A promising frontier
por: Marofi, Faroogh, et al.
Publicado: (2021)

Recent findings on the impact of ErbB receptors status on prognosis and therapy of head and neck squamous cell carcinoma
por: Palumbo, Camilla, et al.
Publicado: (2023)

DNAM-1 Activating Receptor and Its Ligands: How Do Viruses Affect the NK Cell-Mediated Immune Surveillance during the Various Phases of Infection?
por: Cifaldi, Loredana, et al.
Publicado: (2019)

Enhancement of Neuroblastoma NK-Cell-Mediated Lysis through NF-kB p65 Subunit-Induced Expression of FAS and PVR, the Loss of Which Is Associated with Poor Patient Outcome
por: Brandetti, Elisa, et al.
Publicado: (2021)

Editorial: Molecular Strategies Aimed to Boost NK Cell-Based Immunotherapy of Cancer
por: Cifaldi, Loredana, et al.
Publicado: (2020)

The BET-bromodomain inhibitor JQ1 renders neuroblastoma cells more resistant to NK cell-mediated recognition and killing by downregulating ligands for NKG2D and DNAM-1 receptors
por: Veneziani, Irene, et al.
Publicado: (2019)

Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
por: Wu, Xinyu, et al.
Publicado: (2022)

MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma
por: Brandetti, Elisa, et al.
Publicado: (2017)

DNAM-1 controls NK cell activation via an ITT-like motif
por: Zhang, Zhanguang, et al.
Publicado: (2015)

Defective DNAM-1 Dependent Cytotoxicity in Hepatocellular Carcinoma-Infiltrating NK Cells
por: Mantovani, Stefania, et al.
Publicado: (2022)

CAR-NK Cells: A Chimeric Hope or a Promising Therapy?
por: Sabbah, Mohamad, et al.
Publicado: (2022)

Dysregulation of DNAM-1-Mediated NK Cell Anti-Cancer Responses in the Tumor Microenvironment
por: Paolini, Rossella, et al.
Publicado: (2023)

NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development
por: Bashiri Dezfouli, Ali, et al.
Publicado: (2021)

Engineering the next generation of CAR-NK immunotherapies
por: Biederstädt, Alexander, et al.
Publicado: (2021)

CAR-NK cells: A promising cellular immunotherapy for cancer
por: Xie, Guozhu, et al.
Publicado: (2020)

CAR-NK cells for cancer immunotherapy: from bench to bedside
por: Zhang, Leisheng, et al.
Publicado: (2022)

CAR-NK Cell: A New Paradigm in Tumor Immunotherapy
por: Marofi, Faroogh, et al.
Publicado: (2021)

NKG2D and DNAM-1 activating receptors and their ligands in NK-T cell interactions: role in the NK cell-mediated negative regulation of T cell responses
por: Zingoni, Alessandra, et al.
Publicado: (2013)

NK Cells Equipped With a Chimeric Antigen Receptor That Overcomes Inhibition by HLA Class I for Adoptive Transfer of CAR-NK Cells
por: Zhuang, Xiaoxuan, et al.
Publicado: (2022)

Renal cell carcinoma escapes NK cell‐mediated immune surveillance through the downregulation of DNAM‐1
por: Tong, Le, et al.
Publicado: (2023)

T and NK cells: two sides of tumor immunoevasion
por: Fruci, Doriana, et al.
Publicado: (2013)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
por: Lu, Hui, et al.
Publicado: (2021)

PlGF Immunological Impact during Pregnancy
por: Albonici, Loredana, et al.
Publicado: (2020)

Retraction: CAR-NK Cell: a new paradigm in tumor immunotherapy
Publicado: (2023)

Human Induced Pluripotent Stem Cells Are Targets for Allogeneic and Autologous Natural Killer (NK) Cells and Killing Is Partly Mediated by the Activating NK Receptor DNAM-1
por: Kruse, Vanessa, et al.
Publicado: (2015)

Human NK Cells Lyse Th2-Polarizing Dendritic Cells via NKp30 and DNAM-1
por: Walwyn-Brown, Katherine, et al.
Publicado: (2018)

Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
por: Gong, Ying, et al.
Publicado: (2021)

Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire
por: Meazza, Raffaella, et al.
Publicado: (2023)

Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
por: Heipertz, Erica L., et al.
Publicado: (2021)

Engineering CAR-NK cells: how to tune innate killer cells for cancer immunotherapy
por: Schmidt, Dayane, et al.
Publicado: (2022)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
por: Tian, Xiaopeng, et al.
Publicado: (2023)

Inflammatory monocytes and NK cells play a crucial role in DNAM-1–dependent control of cytomegalovirus infection
por: Lenac Rovis, Tihana, et al.
Publicado: (2016)

Dynamic of Circulating DNAM-1+ Monocytes and NK Cells in Patients with STEMI Following Primary Percutaneous Coronary Intervention
por: Kumric, Marko, et al.
Publicado: (2022)

The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy
por: Yu, Yanlin
Publicado: (2023)

Combined treatment with inhibitors of ErbB Receptors and Hh signaling pathways is more effective than single treatment in reducing the growth of malignant mesothelioma both in vitro and in vivo
por: Bei, Roberto, et al.
Publicado: (2022)

Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors
por: Kim, Nayoung, et al.
Publicado: (2021)

You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy
por: Pfefferle, Aline, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tpnfoh8r6gb7n5pmph0dk9gnhu